Table 2.
Expression of PD-L1 among Patients with Type I Tumors Stratified by Baseline Variables (n=75)
| Variables | Intensity of PD-L1 expression |
P-value | ||
|---|---|---|---|---|
| Low expression a (n=26) | High expression b (n=49) | |||
| Age (years) | ||||
| Mean ± SD | 50.5±9.5 | 51.7±9.2 | 0.599 | |
| ≥ 60 | 4 (15.4) | 12 (24.5) | 0.36 | |
| < 60 | 22 (84.6) | 37 (75.5) | ||
| Parity status | ||||
| Nulliparous | 13 (50.0) | 21 (42.9) | 0.554 | |
| Multiparous | 13 (50.0) | 28 (57.1) | ||
| Menopausal status | ||||
| Premenopausal | 15 (57.7) | 19 (38.8) | 0.117 | |
| Postmenopausal | 11 (42.3) | 30 (61.2) | ||
| Stages of disease | ||||
| Stage I-II | 17 (65.4) | 24 (48.9) | 0.174 | |
| Stage III-IV | 9 (34.6) | 25 (51.0) | ||
| Largest tumor size in the ovaries (cm) | ||||
| ≥ 10 | 20 (76.9) | 35 (71.4) | 0.609 | |
| < 10 | 6 (23.1) | 14 (28.6) | ||
| Receiving NAC | 3 (11.5) | 10 (20.4) | 0.334 | |
| Recurrence of disease | 7 (26.9) | 23 (46.9) | 0.092 | |
| Platinum resistance c | 2 (7.7) | 11 (22.4) | 0.108 | |
SD, standard deviation; NACT, neoadjuvant chemotherapy; PD-L1, programmed death ligand-1; a, Positive expression but weaker than placenta (1+); b, Equivalent or stronger to expression in placenta (2+ and 3+); c, Occurring ≤ 6 months following adjuvant platinum chemotherapy.